PDCD1 and nephritis: In relation to the combined drug therapy (anti-PD-1 + anti-CTLA-4), the mean incidence of nephritis reached values around 2%, although the study carried out by Tykody et al. in 2022 evidenced an incidence of nephritis in patients treated with nivolumab + ipilimumab of 3.85% [62].